<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092139</url>
  </required_header>
  <id_info>
    <org_study_id>y (2021) 077</org_study_id>
    <nct_id>NCT05092139</nct_id>
  </id_info>
  <brief_title>Endovascular treatmenT for Acute Ischemic Stroke in China (DETECT2-China)</brief_title>
  <official_title>enDovascular trEatmenT for acutE isChemic sTroke in China (DETECT2-China): a Prospective, National, Multi-center, Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective real world registry study, aiming to explore the effectiveness and&#xD;
      safety of endovascular treatment of acute ischemic stroke in a Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 2</measure>
    <time_frame>Day 90</time_frame>
    <description>the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin Score 0 to 1</measure>
    <time_frame>Day 90</time_frame>
    <description>the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of modified Rankin Score</measure>
    <time_frame>Day 90</time_frame>
    <description>the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in National Institute of Health stroke scale (NIHSS)</measure>
    <time_frame>24 hours, 48 hours, and 2 weeks</time_frame>
    <description>the minimum and maximum values of NIHSS are 0 and 24, respectively; higher NIHSS mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of symptomatic intracranial hemorrhage (sICH)</measure>
    <time_frame>48 hours</time_frame>
    <description>sICH was defined as 4 or more increase in NIHSS caused by hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of death</measure>
    <time_frame>7 days</time_frame>
    <description>death due to any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>neuroimaging associated with clinical outcome</measure>
    <time_frame>48 hours</time_frame>
    <description>neuroimaging included brain CT, MRI or digital subtraction angiography</description>
  </other_outcome>
  <other_outcome>
    <measure>changes in serum biomarkers</measure>
    <time_frame>48 hours</time_frame>
    <description>biomarker included Matrix metalloproteinases, proinflammatory cytokines, and etc.</description>
  </other_outcome>
  <other_outcome>
    <measure>dynamic changes of TCD data associated</measure>
    <time_frame>24 hours</time_frame>
    <description>transcranial Doppler (TCD) data including blood velocity and pulse index, which will be collected at some centers</description>
  </other_outcome>
  <other_outcome>
    <measure>dynamic changes of cortical blood oxygen saturation by near infrared spectroscopy</measure>
    <time_frame>24 hours</time_frame>
    <description>The data will be collected at some centers</description>
  </other_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Stroke, Ischemic</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>endovascular treatment</intervention_name>
    <description>all enrolled patients must receive endovascular treatment</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        acute ischemic stroke with large vessel oclussion&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥ 18;&#xD;
&#xD;
          -  Ischemic stroke confirmed by head CT or MRI;&#xD;
&#xD;
          -  Patients receiving endovascular treatment;&#xD;
&#xD;
          -  First ever stroke or pre-stroke mRS≤2;&#xD;
&#xD;
          -  signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prestroke mRS≥3;&#xD;
&#xD;
          -  Other serious illness that would confound the clinical outcome at 90 days;&#xD;
&#xD;
          -  Unavailable neuroimaging data;&#xD;
&#xD;
          -  Other unsuitable conditions judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Northern Theater Command</name>
      <address>
        <city>ShenYang</city>
        <zip>110840</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Head of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

